HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All OTC Ingredient TEAs Get Review Deadlines In Senate Draft Bill

This article was originally published in The Rose Sheet

Executive Summary

Senate HELP committee leaders release a draft bill for discussion that builds on the Sunscreen Innovation Act and its proposed deadlines for FDA review of sunscreen TEA applications, adding provisions that would require FDA to set “reasonable” review deadlines for all OTC ingredient TEAs.

You may also be interested in...

Short Window For Senate, House To Agree On TEA Review Deadlines For FDA

The Senate approves an amended version of the Sunscreen Innovation Act by unanimous consent, with a view toward speeding FDA reviews for all OTC ingredient TEAs. The House version addresses only sunscreen TEAs, and reconciliation of the two chambers’ bills likely will have to wait for the lame duck session.

Senators Optimistic As Sunscreen Bill Heads For HELP Committee Markup

Ahead of a Sept. 17 committee markup of the Senate’s Sunscreen Innovation Act, bill sponsors and stakeholders held a briefing on Capitol Hill to generate support for the legislation, which has already passed in the House. The bill, S. 2141, has 15 co-sponsors and is expected to advance through committee to the Senate floor.

CHPA “Neutral” On Requiring Deadlines For TEA Reviews

CHPA comments on the Senate HELP Committee’s draft legislation that would require FDA to establish review deadlines for TEAs. The trade group says it is “neutral” about the proposal, but offers to help the committee with “more comprehensive reviews of OTC approvals.”

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts